OVERVIEW

Managing obesity has evolved over time and led to a variety of management approaches. One of the effective treatment modalities is pharmacological interventions, including the use of GLP-1-based medications to address the unique needs of a person living with obesity. Join us for an overview of the current GLP-1-based medications that are currently available and are coming to market. Participants will gain insights into pharmacotherapy for obesity management, including the appropriate use, short-term side effects, and the impact they can have on other complications.

LEARNING OBJECTIVES

• Recall and describe the evolution of obesity management approaches and the introduction of GLP-1-based medications currently available and near market approval.
• Understand and describe the mechanism of action GLP-1-based medications have on obesity.
• Recognize common short-term side effects associated with using GLP-1-based medications.
• Identify the positive impact GLP-1-based medications can have on obesity related complications.

DATE & TIME

September 17, 2025 from 4:00 PM - 5:00 PM ET

Novo Nordisk is a strategic supporter of the Obesity Association, a division of the American Diabetes Association.

Note: You do not need to be an ADA professional member to access our free continuing education programs. Simply create a free account and start exploring 70+ free CE courses. Login to get started!